Compare DHIL & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHIL | KMDA |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 458.6M |
| IPO Year | 1996 | 2013 |
| Metric | DHIL | KMDA |
|---|---|---|
| Price | $172.61 | $8.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 21.4K | ★ 65.5K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.48% | 2.21% |
| EPS Growth | ★ 14.37 | N/A |
| EPS | ★ 17.91 | N/A |
| Revenue | ★ $145,201,729.00 | N/A |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | N/A | $11.38 |
| P/E Ratio | ★ $9.61 | $24.59 |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $114.11 | $5.54 |
| 52 Week High | $173.00 | $9.35 |
| Indicator | DHIL | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 65.89 | 56.02 |
| Support Level | $170.59 | $6.69 |
| Resistance Level | N/A | $9.35 |
| Average True Range (ATR) | 0.69 | 0.27 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 68.88 | 60.00 |
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.